LEGN LEGEND BIOTECH CORP

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results.

During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.

Investors and other interested parties may join the live audio webcast of the call via this .

A replay version of the webcast and earnings news release will be available through the section of Legend Biotech’s website under the section approximately two hours after the call concludes.

ABOUT LEGEND BIOTECH

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at  and follow us on  and .

INVESTOR CONTACT:

Jessie Yeung

Tel: (732) 956-8271

PRESS CONTACT:

Mary Ann Ondish

Tel: (914) 552-4625





EN
10/07/2024

Underlying

LEGNLEGEND BIOTECH CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LEGEND BIOTECH CORP

 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Conference Call on Second Quarter 2025...

Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results SOMERSET, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, August 11, 2025, to review second-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this . A replay of the webcast ...

July 28, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKT...

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years CARTITUDE-4 subgroup analyses featured in a poster presentation highlight consistent, durable progression-free and overall survival benefit vs. standard therapies across cytogenetic risk groups as early as second-line therapyPromising early results from ongoing Phase...

June 3, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Devel...

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® infusion New data at ASCO from the CARTITUDE-4 study to showcase improved progression-free survival and overall survival with CARVYKTI® versus standard of care (SOC) in key subgroups Preliminary results from ongoing Phase 1 dose-escalation studies of LB2102 in lung cancers and LB1908 in gastroes...

May 22, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Event During the 2025 American Society...

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinici...

May 19, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlight...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® labelAustralia’s TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.0 billion, as of March 31, 2025, which Legend Biot...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch